Table 1 Comparison of characteristics between the survival and fatality groups

Gender

0.044

 Male

17 (56.7)

13 (86.7)

 Female

13 (43.3)

2 (13.3)

0.104

Age (years)

13 (4-19)

11 (1-19)

0.111

Underlying disease

0.296

 Acute myeloid leukemia

12 (40.0)

7 (46.7)

 Acute lymphoblastic leukemia

13 (43.3)

4 (26.7)

 Severe aplastic anemia

5 (16.7)

2 (13.3)

 Undifferentiated acute leukemia

0 (0.0)

1 (6.7)

 Non-Hodgkin lymphoma

0 (0.0)

1 (6.7)

Remission status of the underlying disease^a

0.016

 Complete remission status

9 (36.0)

0 (0.0)

 Not complete remission status

16 (64.0)

13 (100.0)

1.000

Type of preceding chemotherapy

0.035

 No chemotherapy

6 (20.0)

1 (6.7)

 Induction

4 (13.3)

0 (0.0)

1.000

 Re-induction or salvage

9 (30.0)

9 (60.0)

0.999

 Consolidation

4 (13.3)

0 (0.0)

1.000

 Maintenance

1 (3.3)

0 (0.0)

1.000

 Palliative

1 (3.3)

4 (26.7)

0.999

 Allogeneic hematopoietic cell transplantation

5 (16.7)

1 (6.7)

1.000

Previous history of hematopoietic cell transplantation

14 (46.7)

8 (53.3)

0.673

Previous history of invasive aspergillosis

4 (13.3)

1 (6.7)

0.651

Duration of fever (days)

2 (0–10)

3 (0–17)

0.419

Duration of neutropenia at the beginning of antifungal therapy

1.000

 ≤2 weeks

14 (46.7)

7 (46.7)

 >2 weeks

16 (53.3)

8 (53.3)

Presence of other accompanying infections

11 (36.7)

4 (26.7)

0.502

Chest computed tomography findings

 Consolidations with a halo sign

21 (70.0)

14 (93.3)

0.129

 Consolidations without a halo sign

9 (30.0)

1 (6.7)

0.129

 Air-crescent sign

0 (0.0)

0 (0.0)

NA

 Cavity

1 (3.3)

1 (6.7)

1.000

Positive serum galactomannan results

23 (76.7)

14 (93.3)

0.234